Jason J. Luke, MD, on Melanoma Adjuvant Therapy: Final Analysis of KEYNOTE-716
2023 ASCO Annual Meeting
Jason J. Luke, MD, of the University of Pittsburgh Medical Center Hillman Cancer Center, discusses adjuvant pembrolizumab, which, in previous results, improved distant metastasis– and recurrence-free survival in patients with resected stage IIB or IIC melanoma vs placebo. After a median follow-up of 39.4 months, adjuvant pembrolizumab continued to show a benefit over placebo, with no new safety signals (Abstract LBA9505).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Adjuvant therapy for melanoma has been shifting rapidly and really to the betterment to the patients that were treated in our clinics. KEYNOTE-716 was the placebo controlled phase three clinical trial that demonstrated that pembrolizumab improves recurrence-free and distant metastasis free survival for patients with 2B and 2C melanoma. And of course, the context for this clinical trial was that we've been using adjuvant therapy for stage three melanoma for several years, and yet it wasn't available for patients with stage two. But that being said, the melanoma specific survival of patients with stage 2B and 2C melanoma has been known to actually be worse than that for patients with stage 3A and 3B melanoma, and yet we couldn't treat them. So we launched KEYNOTE-716 really to try to level set the field to give access to patients for a treatment that we know works for patients with similar risk.
So to update the study now, we're presenting Landmark 36 month data with a median of 39 months of follow-up, showing that the recurrence-free survival, but more importantly, distant metastases free survival continues to be maintained and in fact increases in magnitude of benefit with further follow up on the clinical trial. And these are very, very important data for multiple reasons. One, is that they really emphasize this point that patients with stage 2B and 2C melanoma are at high risk of recurrence. But more than that, that adjuvant pembrolizumab is now the standard of care that should be offered to these patients.
Now, of course, there is nuance to the decision about whether or not to choose adjuvant therapy in the postoperative setting. We have to take into account the risks and the benefits. It's clear now that the benefits include more than a 4% reduction in the likelihood of distant metastasis. There are side effects that are associated with immunotherapy, immune related adverse events, which no doubt can take place and be life altering in up to 5% of patients. So that's really where the crux is. With an individual patient, is it worth it to consider an adjuvant therapy that can significantly reduce your risk, albeit potentially also enhance side effect profile?
So I think these data are very important to level set the field. Again, this is a very rapidly moving field, and these data show the landmarks and the benchmarks of what we should expect moving forward. There are multiple adjuvant clinical trials, phase three randomized studies that are now looking to further enhance the standard of care. And these include checkpoint combinations with molecules targeting lag three and tigit, and more recently, the individualized neo antigen therapies that have looked very, very promising. And so we know now that patients with stage two should be included in those clinical trials, and in fact, they are. And I think for the future moving forward, the perioperative setting for adjuvant therapy really will include all patients with stage 2B all the way through stage four resected melanoma.
Related Videos
The ASCO Post Staff
Bradley J. Monk, MD, of the University of Arizona, Phoenix, and Creighton University, discusses phase III findings from the KEYNOTE-826 study of overall survival results in patients with persistent, recurrent, or metastatic cervical cancer. Study participants received first-line treatment of pembrolizumab plus chemotherapy, with or without bevacizumab, which reduced the risk of death by up to 40% in three different subsets of patients (Abstract 5500).
The ASCO Post Staff
Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Kathleen N. Moore, MD, of the Stephenson Oklahoma Cancer Center at the University of Oklahoma, discuss phase III results from the MIRASOL trial, which showed that mirvetuximab soravtansine-gynx prolonged overall survival vs investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer with high folate receptor-alpha expression. The findings suggest a new standard of care for this disease (Abstract LBA5507).
The ASCO Post Staff
Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses phase II results showing that split-dose R-CHOP offers older patients with diffuse large B-cell lymphoma (DLBCL) an equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule, improving tolerability. At the end of treatment for these older patients, a complete response rate of 71% was comparable to outcomes with R-CHOP in younger patients with the disease (Abstract 7554).
The ASCO Post Staff
Omid Hamid, MD, of The Angeles Clinic & Research Institute, discusses study findings on fianlimab plus cemiplimab-rwlc, which showed clinical activity in patients with advanced melanoma, comparing favorably with other approved combinations of immune checkpoint inhibitors in the same clinical setting. This is the first indication that dual LAG-3 blockade may produce a high level of activity with significant overall response rate after adjuvant anti–PD-1 treatment. A phase III trial of this regimen in treatment-naive patients with advanced melanoma is ongoing (Abstract 9501).
The ASCO Post Staff
Tycel J. Phillips, MD, of City of Hope National Medical Center, and Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and the International Extranodal Lymphoma Study Group, discuss findings from the largest prospective study of patients with primary mediastinal B-cell lymphoma. The trial data support omitting radiotherapy in patients who achieve complete metabolic response after immunochemotherapy (Abstract LBA7505).